✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

CJC-1295 with DAC vs without DAC: Albumin-Bound Long-Acting vs Pulse-Preserving Short-Acting

“CJC-1295” is two molecules sold under the same name — both are GHRH analogues with the same core sequence and the same receptor pharmacology, but differ entirely in plasma half-life and therefore in research application. The differentiator is a single chemical modification: the DAC (Drug Affinity Complex). This guide covers what that modification does, why the two variants are used for different research questions, and how to pick between them.

What DAC actually is

DAC (Drug Affinity Complex) is a maleimidopropionyl modification at the N-terminus of the CJC-1295 peptide. The maleimide group reacts covalently with the free thiol on cysteine-34 of circulating serum albumin — the most abundant blood protein. Once bound, the peptide effectively becomes a long-lived albumin conjugate, with the same plasma half-life as albumin itself (~19-21 days for human albumin, though the practical functional half-life on the GH-pulse readout is closer to 4-8 days because of receptor desensitisation and pharmacodynamic-vs-pharmacokinetic decoupling).

Without DAC, the peptide is the unmodified Mod-GRF 1-29 sequence with four enzymatic-stability substitutions (D-Ala2, Gln8, Ala15, Leu27) that protect against aminopeptidase degradation without extending half-life beyond the natural ~30-minute window. Mechanistically: same GHRH-receptor binding, same intrinsic activity, same pulse-pharmacology when present at the receptor — just absent from plasma minutes after administration.

Comparison table

Why pulsatility matters (or doesn’t) in research design

The somatotropic axis evolved to operate in pulses. Endogenous GH is released in 5-7 discrete pulses per 24 hours, with the largest pulse coinciding with slow-wave sleep onset. The pulsatile pattern matters because GH-receptor signalling shows complex dose-response behaviour — receptor desensitisation accumulates under sustained agonist exposure, whereas pulse-pattern exposure preserves receptor responsiveness across pulses.

For research-protocol design, this creates a clean split:

• If your research question is “what does pulse-matched natural GH elevation do?”: Use without-DAC CJC. The 30-minute half-life produces a pulse matching natural pituitary release, particularly when dosed pre-sleep alongside Ipamorelin in the synergistic stack.
• If your research question is “what does sustained elevated GH/IGF-1 do?”: Use with-DAC CJC. The sustained plasma elevation tonically activates the GHRH receptor, producing a chronic “GH bleed” pattern that is mechanistically distinct from natural pulsatility.

The two questions produce different downstream pharmacology, different IGF-1 elevation profiles, and different receptor-desensitisation dynamics. Neither is “better” — they answer different research questions.

Which to pick (research-protocol logic)

• Synergistic CJC + Ipamorelin stack research: CJC-1295 without DAC. The pulse-preservation matters for the synergy logic. See: CJC-1295 + Ipamorelin stack guide.
• Chronic IGF-1 elevation research: CJC-1295 with DAC. Weekly dosing produces sustained plasma elevation.
• Pulse-pattern-preserving body-composition research: Without DAC.
• Convenience-driven long-duration protocols: With DAC (weekly vs daily dosing).
• Both variants in the same research design: Valid — some published protocols use both to characterise pulse-vs-tonic GHRH-receptor pharmacology.

FAQ

Are with-DAC and without-DAC actually the same peptide underneath?

Yes, the core 29-amino-acid sequence is identical. Both have the same four enzymatic-stability substitutions (D-Ala2, Gln8, Ala15, Leu27) that protect against aminopeptidase degradation. The only difference is the N-terminal maleimidopropionyl group on the with-DAC variant. When the with-DAC peptide is released from its albumin binding (which happens slowly over days), the binding-competent form acts on the GHRH receptor identically to the without-DAC variant.

Why is the without-DAC variant called “Mod-GRF 1-29”?

Because that’s its original research-literature designation. GRF (growth hormone-releasing factor) 1-29 is the 29-amino-acid minimum active fragment of native GHRH. “Mod” refers to the four modifications added for enzymatic stability. The original developer (ConjuChem) named the with-DAC variant “CJC-1295” specifically — but in popular usage and on most research-supply catalogues, the name “CJC-1295” has been applied to both variants, with the “with DAC” or “without DAC” disambiguator added.

What’s the actual half-life of the with-DAC variant?

Two answers. Pharmacokinetic half-life (time for plasma concentration to halve): essentially albumin’s half-life, ~19-21 days. Functional half-life (time for the GH-pulse-stimulating effect to halve): substantially shorter at 4-8 days, due to GHRH-receptor desensitisation under sustained exposure. Published research uses the 4-8 day functional half-life as the practical protocol-design parameter.

Can I stack with-DAC CJC-1295 with Ipamorelin?

Yes, but the synergy logic is different. The classical CJC + Ipamorelin stack uses without-DAC because the goal is to amplify a natural pulse pattern — the GHRH and GHRP arms fire together to produce a synergistic pulse. With-DAC CJC produces sustained GHRH-receptor activation; Ipamorelin pulses on top of that produce a different mechanism (Ipamorelin pulse on a saturated GHRH-receptor baseline). Both are valid research designs, just different ones.

Is the with-DAC variant safer because dosing is less frequent?

Not necessarily. Less frequent dosing reduces the operational burden of the protocol but the sustained GH/IGF-1 elevation produces a different pharmacology profile that has its own considerations — specifically, increased risk of receptor desensitisation, more sustained insulin-resistance effects, and a longer washout period if the protocol needs to be terminated quickly. “Safer” depends on the specific research scenario.

What’s the dose comparison?

Without DAC: ~100 mcg per administration (research protocols vary 100-300 mcg). With DAC: ~1-2 mg per weekly dose (research protocols vary). The dose difference reflects the activity-per-administration profile — without-DAC delivers a brief intense pulse, with-DAC delivers sustained elevation over days.

Storage protocol?

Same for both: lyophilized vials at -20 °C long-term or 2-8 °C as working stock; reconstituted with bacteriostatic water; reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw.

Bottom line

The two variants of CJC-1295 are mechanistically the same peptide differing in plasma half-life by orders of magnitude. Without DAC is the pulse-preserving variant used in the classical CJC + Ipamorelin synergistic stack; with DAC is the sustained-elevation variant for chronic-exposure research and convenience-driven dosing. Pick based on whether your research question is about natural-pattern GH pulsatility (without DAC) or sustained GHRH-receptor activation (with DAC). See Best growth hormone peptides for full GH-axis cluster context.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.